Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective.
Jinsui ZhangZemin XiaWanjie GuoXiaoxiao RenFang LiuGargi RatnaparkhiAmit PagadaSubhashini SubramanianMin HuWen ChenPublished in: Dermatology and therapy (2023)
Secukinumab is the most cost-effective treatment option for patients with moderate-to-severe psoriasis compared with other commonly used biologics from the Chinese healthcare system perspective.